Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Media

Company News

Mar 16

2020

Hua Medicine Announces 2019 Annual Results

Hua Medicine (the"Company", Stock Code on The Stock Exchange of Hong Kong Limited: 2552.HK), a global innovative drug research and development company focused on novel therapies for the treatment of diabetes, today announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2019. For the year ended December 31, 2019, the Company incurred approximately RMB468.5 million in total expenses, of which approximately RMB 321.9 million was research and development expenses. As of December 31, 2019, the Company’s cash position was approximately RMB 1,105.6 million.

Feb 25

2020

Congratulations to Franz Matschinsky, Winner of the Rolf Luft Award 2020

Franz Matschinsky, Professor of Biochemistry and Biophysics, Institute for Diabetes, Obesity and Metabolism Perelman School of Medicine, Philadelphia, was awarded the Rolf Luft Award 2020. Dr. Matschinsky was recognized "for the discovery that glucokinase (GK) is the sensor controlling glucose-stimulated insulin secretion in the pancreatic β-cell".

Feb 14

2020

Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer

Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, is pleased to announce that Dr. Fuxing Tang has joined Hua Medicine as Chief Technology Officer, VP of Formulation R&D and Product Development. He will also head up research and development functions for Hua Medicine in the United States.

Jan 06

2020

Hua Medicine Announces Positive Results of HMM0110 and HMM0111

Hua Medicine today announced the clinical study results of HMM0110 and HMM0111. HMM0110 was conducted in China to evalsuate whether dorzagliatin can be readily used in Type 2 diabetes (T2D) patients with impaired renal function. In subjects with end stage renal disease (ESRD, eGFR

Nov 25

2019

Hua Medicine Presents First Public Academic Report on Phase III Registration Trial Results of its Global First-in-Class Drug

11月22日，在2019CDS大会（中华医学会糖尿病学分会第二十三次全国学术会议）上，中华医学会糖尿病学分会主任委员、南京鼓楼医院内分泌科主任朱大龙教授，首次在大会举办的糖尿病治疗循证医学证据研讨会上公开报告Z6·尊龙凯时「中国」官方网站医药在研全球首创新药——双重机制葡萄糖激酶激活剂（GKA）Dorzagliatin在未用药2型糖尿病患者中开展的单药治疗III期注册临床研究（HMM0301）结果。

Nov 25

2019

Good News: Hua Medicine’s Global First-in-Class Drug Was Presented at 2019 Scientific Meeting of CDS

On November 21st, the 2019 CDS Meeting (the 23rd Scientific Meeting of the Chinese Diabetes Society) was held in Xiamen. The Phase III clinical study results of dorzagliatin (HMS5552), the global first dual-acting glucokinase activator, were presented in the plenary session.

Nov 12

2019

Hua Medicine’s Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Glucokinase Modulator, Achieves Primary Efficacy Endpoint in Patients with Type 2 Diabetes

Phase III Monotherapy Trial (HMM0301) of Dorzagliatin Achieves Primary Efficacy Endpoint with 24-Week Topline Results

Nov 08

2019

Hua Medicine to Release Phase III 24-Weeks Topline Data of Dorzagliatin Monotherapy Trial (HMM0301) on November 12

Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of type 2 diabetes, today announced that 24-week topline data of dorzagliatin’s monotherapy trial (HMM0301) will be released on November 12, 2019, and management will present the results and answer any questions via conference call.

Aug 30

2019

Hua Medicine completes patient enrollment for Phase III combination with metformin trial of dorzagliatin

Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, announced today the completion of patient enrollment for a Phase III combination trial of HMS5552 (dorzagliatin) add on to metformin.

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.